Sunshine Act

CMI/Compas conducted research to gauge and compare perceptions of the Sunshine Act – including understanding of reportable and exempt items – from two perspectives: physicians and pharma industry (clients/partners). This research discovered distinct viewpoints:

  • Physicians would benefit from understanding what items are reportable and what items are exempt
  • Pharma Industry should not back away from providing valuable materials to PCPs, as they are still viewed as beneficial by physicians
  • By using visual aids, such as the CMI/Compas proposed exempt/reportable emblems, Pharma can assist physicians in quickly identifying what is reportable and what is exempt

View full results of the study here

View a list of the top pharma companies’ Sunshine Act policies here

PM360 The Sunshine Act’s Crackdown on Medical Reprints – What Pharma Can Do About It
– Article by CMI/Compas experts about the impact of The Sunshine Act on reprint marketing

The Sunshine Act Infographic
– A visual representation of the law and what is reportable

For more information on how CMI/Compas can guide you, contact Lindsay Dinan at sales@cmicompas.com


If you’d like to receive future insights and news from us please share your contact information and select the information you’d like to receive

First Name* Last Name*
Email* Title
Company Phone
*Required
 Scoop: A daily summary of the most current healthcare and tech news, with a small dash of snark Insider Scoop: A monthly recap of the most important news in healthcare and publishing Customer Insights: Reports only CMI/Compas can provide Thought Leadership:- POVs and whitepapers with insights only CMI/Compas can provide, sent anytime a hot topic hits Marketing/Products: Up-to-the-minute updates on our latest products and services